MacWalterRS. Strategies to prevent further cerebral ischaemic episodes. Scot Med J, 1997; 42: 135.
2.
Stroke Prevention in Atrial Fibrillation Investigators: The Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation1991; 84: 527.
3.
European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet1993; 342, 1255–62.
4.
PetersenPBoysenGGodtfredsenJAndersenEDAndersenB. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet, 1989; 1, 175–79.
5.
Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from three randomized trials. Arch Intern Med1997; 157, 1237–40.
6.
BousserMGEschwegeEHaguenauM. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischaemia. Stroke, 1983; 14: 5–14.
7.
American-Canadian Co-Operative Study Group. Persantine aspirin trial in cerebral ischaemia. Part II. Endpoint results. Stroke1985; 16: 406–15.
8.
ESPS Group. The European Stroke Prevention Study: Principal Endpoints. Lancet1987; ii: 1351–54.
9.
DienerHCunhaLForbesCSiveniusJSmetsPLowenthalA. European Stroke Prevention Study 2. Dipyridamole and acetylsalcylic acid in the secondary prevention of stroke. J Neurol Sciences, 1996; 143: 1–13.
10.
GibbsCRLipGYH. Do we still need Dipyridamole?Br J Clin Pharm1998 (in press).
